$KALV
KalVista Pharmaceuticals, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022026230 Filed on December 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2021 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.806M $6.057M
YoY Change 28.88% 66.86%
% of Gross Profit
Research & Development $18.08M $17.55M
YoY Change 3.03% 91.8%
% of Gross Profit
Depreciation & Amortization $173.0K $127.0K
YoY Change 36.22% -2.31%
% of Gross Profit
Operating Expenses $25.88M $23.60M
YoY Change 9.66% 84.67%
Operating Profit -$25.88M -$23.60M
YoY Change 9.66% 84.67%
Interest Expense $132.0K $10.00K
YoY Change 1220.0% -94.12%
% of Operating Profit
Other Income/Expense, Net $3.626M $3.953M
YoY Change -8.27% 67.86%
Pretax Income -$22.26M -$19.65M
YoY Change 13.27% 88.4%
Income Tax
% Of Pretax Income
Net Earnings -$22.26M -$19.65M
YoY Change 13.27% 88.47%
Net Earnings / Revenue
Basic Earnings Per Share -$0.90 -$0.80
Diluted Earnings Per Share -$0.90 -$804.0K
COMMON SHARES
Basic Shares Outstanding 24.60M 24.47M
Diluted Shares Outstanding 24.60M 24.44M

Balance Sheet

Concept 2022 Q4 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $122.3M $209.8M
YoY Change -41.72% 275.34%
Cash & Equivalents $38.59M $46.49M
Short-Term Investments $83.69M $163.3M
Other Short-Term Assets $7.013M $7.266M
YoY Change -3.48% 384.4%
Inventory
Prepaid Expenses $5.101M
Receivables
Other Receivables
Total Short-Term Assets $151.2M $234.5M
YoY Change -35.51% 225.21%
LONG-TERM ASSETS
Property, Plant & Equipment $3.060M $2.180M
YoY Change 40.37% -31.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $197.0K $193.0K
YoY Change 2.07% -3.5%
Total Long-Term Assets $11.62M $9.332M
YoY Change 24.54% 182.79%
TOTAL ASSETS
Total Short-Term Assets $151.2M $234.5M
Total Long-Term Assets $11.62M $9.332M
Total Assets $162.8M $243.8M
YoY Change -33.21% 223.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.384M $3.159M
YoY Change 7.12% 43.59%
Accrued Expenses $6.910M $6.025M
YoY Change 14.69% -18.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.32M $10.11M
YoY Change 11.92% 6.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.705M $6.224M
YoY Change 23.79% 591.56%
Total Long-Term Liabilities $7.705M $6.224M
YoY Change 23.79% 591.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.32M $10.11M
Total Long-Term Liabilities $7.705M $6.224M
Total Liabilities $19.03M $16.34M
YoY Change 16.45% 55.6%
SHAREHOLDERS EQUITY
Retained Earnings -$295.5M -$203.6M
YoY Change 45.14%
Common Stock $444.6M $432.8M
YoY Change 2.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $143.8M $227.5M
YoY Change
Total Liabilities & Shareholders Equity $162.8M $243.8M
YoY Change -33.21% 223.36%

Cashflow Statement

Concept 2022 Q4 2021 Q4
OPERATING ACTIVITIES
Net Income -$22.26M -$19.65M
YoY Change 13.27% 88.47%
Depreciation, Depletion And Amortization $173.0K $127.0K
YoY Change 36.22% -2.31%
Cash From Operating Activities -$20.59M -$19.55M
YoY Change 5.37% 145.85%
INVESTING ACTIVITIES
Capital Expenditures -$192.0K -$356.0K
YoY Change -46.07% 1680.0%
Acquisitions
YoY Change
Other Investing Activities $20.29M $18.00M
YoY Change 12.73% 182.12%
Cash From Investing Activities $20.10M $17.64M
YoY Change 13.91% 176.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 168.0K 63.00K
YoY Change 166.67% 5.0%
NET CHANGE
Cash From Operating Activities -20.59M -19.55M
Cash From Investing Activities 20.10M 17.64M
Cash From Financing Activities 168.0K 63.00K
Net Change In Cash -328.0K -1.839M
YoY Change -82.16% 20.99%
FREE CASH FLOW
Cash From Operating Activities -$20.59M -$19.55M
Capital Expenditures -$192.0K -$356.0K
Free Cash Flow -$20.40M -$19.19M
YoY Change 6.32% 141.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Amendment Flag
AmendmentFlag
false
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q2 us-gaap Assets
Assets
203880000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3384000
dei Entity Central Index Key
EntityCentralIndexKey
0001348911
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--04-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-10-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36830
dei Entity Registrant Name
EntityRegistrantName
KALVISTA PHARMACEUTICALS, INC.
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-0915291
dei Entity Address Address Line1
EntityAddressAddressLine1
55 Cambridge Parkway
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 901E
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
999-0075
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
KALV
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24618150
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38585000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30732000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
83688000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
135470000
CY2022Q4 kalv Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
20029000
CY2022Q2 kalv Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
14098000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8914000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13347000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
151216000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
193647000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3060000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2178000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8365000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7862000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
197000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
193000
CY2022Q4 us-gaap Assets
Assets
162838000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3638000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6910000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
us-gaap Investment Income Interest
InvestmentIncomeInterest
564000
CY2022Q4 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-317000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6961000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1026000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
977000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11320000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
11576000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7705000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7211000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
7705000
CY2022Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
7211000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24602023
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24602023
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24550748
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24550748
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
25000
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
25000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
444588000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
439104000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-295474000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-250175000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5326000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3861000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
143813000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
185093000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
162838000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
203880000
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18077000
CY2021Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17546000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36262000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31215000
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7806000
CY2021Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6057000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15936000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11903000
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
25883000
CY2021Q4 us-gaap Operating Expenses
OperatingExpenses
23603000
us-gaap Operating Expenses
OperatingExpenses
52198000
us-gaap Operating Expenses
OperatingExpenses
43118000
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-25883000
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-23603000
us-gaap Operating Income Loss
OperatingIncomeLoss
-52198000
us-gaap Operating Income Loss
OperatingIncomeLoss
-43118000
CY2022Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
449000
CY2021Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3953000
CY2021Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
290000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6899000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7360000
us-gaap Investment Income Interest
InvestmentIncomeInterest
691000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-22257000
CY2021Q4 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-280000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-834000
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-19650000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-331000
CY2022Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3494000
CY2021Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3943000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7042000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7127000
CY2022Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3626000
us-gaap Net Income Loss
NetIncomeLoss
-45299000
us-gaap Net Income Loss
NetIncomeLoss
-35758000
CY2022Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1297000
CY2021Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-33000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1700000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
16000
CY2022Q4 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
52000
CY2021Q4 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-295000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
150000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-424000
CY2022Q4 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-69000
CY2021Q4 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-97000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-85000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-120000
CY2022Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1176000
CY2021Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-231000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1465000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-288000
CY2022Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23433000
CY2021Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19881000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46764000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36046000
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.90
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.90
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.80
CY2021Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.80
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.46
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24595039
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24595039
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24439623
CY2021Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24439623
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24576327
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24576327
CY2022Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1297000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24434852
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24434852
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
185093000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
168000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2642000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-23042000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-403000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
98000
CY2022Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-16000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
164572000
CY2022Q4 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
168000
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2506000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-22257000
CY2022Q4 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
52000
CY2022Q4 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-69000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
143813000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
257193000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
608000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2795000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-16109000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
49000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-129000
CY2021Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-23000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
244430000
CY2021Q4 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
63000
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2860000
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-19650000
CY2021Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-33000
CY2021Q4 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-295000
CY2021Q4 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-97000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
227472000
us-gaap Profit Loss
ProfitLoss
-45299000
us-gaap Profit Loss
ProfitLoss
-35758000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
331000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
259000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5148000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5655000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-85000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-120000
kalv Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
42000
kalv Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
46000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
678000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1424000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
739000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-266000
kalv Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
7137000
kalv Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
7252000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3650000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2419000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-81000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
671000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1163000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-14000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-784000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43336000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37280000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
10102000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
51695000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
61356000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
84862000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1112000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
643000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
50142000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
32524000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
336000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
336000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
671000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
711000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-16000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7853000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4101000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30732000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
50592000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
38585000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
46491000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1192000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
132000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
39000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-295500000
CY2022Q4 kalv Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
122300000
CY2022Q4 kalv Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
9906000
CY2022Q4 kalv Available For Sale Securities Debt Maturities After Two Through Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeYearsFairValue
2465000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
83688000
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
27389000
CY2022Q4 kalv Cash And Cash Equivalents And Marketable Securities Fair Value Disclosure
CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure
111077000
CY2022Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
13735000
CY2022Q2 kalv Cash And Cash Equivalents And Marketable Securities Fair Value Disclosure
CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure
149205000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
84582000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
894000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
83688000
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
136599000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1131000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
135470000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
71317000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1845000
CY2022Q4 kalv Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
3387000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
11394000
CY2022Q4 kalv Lessee Operating Lease Liability Minimum Payments Interest Included In Payments
LesseeOperatingLeaseLiabilityMinimumPaymentsInterestIncludedInPayments
2663000
CY2022Q4 kalv Lessee Operating Lease Liability Present Value Of Net Minimum Payments
LesseeOperatingLeaseLiabilityPresentValueOfNetMinimumPayments
8731000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1026000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7705000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3091000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4168000
CY2022Q4 kalv Accrued Research Expense Current
AccruedResearchExpenseCurrent
2549000
CY2022Q2 kalv Accrued Research Expense Current
AccruedResearchExpenseCurrent
2011000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1046000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
474000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
224000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
308000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6910000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6961000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5101000
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
8404000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1912000
CY2022Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2234000
CY2022Q4 us-gaap Interest Receivable And Other Assets
InterestReceivableAndOtherAssets
666000
CY2022Q2 us-gaap Interest Receivable And Other Assets
InterestReceivableAndOtherAssets
888000
CY2022Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
1235000
CY2022Q2 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
1821000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8914000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13347000
CY2022Q4 kalv Contractual Obligations Remaining Commitment Including Cancellation Provisions
ContractualObligationsRemainingCommitmentIncludingCancellationProvisions
27000000.0
kalv Amount Associated With Indemnification
AmountAssociatedWithIndemnification
0
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
853000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1733000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1769000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1807000

Files In Submission

Name View Source Status
0000950170-22-026230-index-headers.html Edgar Link pending
0000950170-22-026230-index.html Edgar Link pending
0000950170-22-026230.txt Edgar Link pending
0000950170-22-026230-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
kalv-20221031.htm Edgar Link pending
kalv-20221031.xsd Edgar Link pending
kalv-ex31_1.htm Edgar Link pending
kalv-ex31_2.htm Edgar Link pending
kalv-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
kalv-20221031_cal.xml Edgar Link unprocessable
kalv-20221031_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
kalv-20221031_pre.xml Edgar Link unprocessable
kalv-20221031_lab.xml Edgar Link unprocessable
kalv-20221031_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending